Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Maar eens zien of hij zin en tijd heeft ;)rheumatologe.blogspot.com/ Sehr geehrter Herr Dr. Kirsch, Könnten Sie auf Ihrer Blogseite mal stellungnehmen zu Filgotinib von Galapagos? Filgo steht kurz vor der Marktzulassung durch die FDA und EMA. Die Galapagos-investoren sind momentan insbesondere daran interessiert, ob Filgo eine eventuelle, (JAK-)klassenbreite sogen. “Black Box Warning” bekommt und ob es möglicherweise zu beschränkungen bezüglich der 200Mg-Dosis kommen wird. Ich werde diese E-mail und Ihre eventuelle Stellungnahme (mittels Ihrer Blog- Seite) auf Anlegerfora posten. Mit freundlichen Grüssen, K. Wiebeswww.glpg.com/press-releases www.fiercepharma.com/pharma/abbvie-s-...
Key Trading Events / Clinical Development Calendar
belangrijkste wijzigingen staan op sheet 46 en 50.
Gilead Sciences to Release Second Quarter 2020 Financial Results on Thursday, July 30, 2020 FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced that its second quarter 2020 financial results will be released on Thursday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s second quarter 2020 financial results and will provide a business update.Don't forget to tune in for the conference call. The live webcast of the call can be accessed at the company’s Investors page at investors.gilead.com. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast.Galapagos 06 August, 2020 Half year 2020 resultsWebcast 07 August 2020, 14.00 CET Dial-in details coming soon
3 Top Coronavirus Stocks to Buy Right Now Adria Cimino Jul 19, 2020 at 9:00AM Gilead Sciences The U.S. Food and Drug Administration (FDA) granted Gilead Sciences (NASDAQ: GILD) emergency use authorization for its COVID-19 treatment, remdesivir, in May. The company donated its initial stock of the drug, but recently set a price and is now transitioning to selling the treatment. Gilead's investment has been steep. The company estimates it will have spent $1 billion by the end of the year. But at $2,340 per patient for a five-day treatment course, and considering a Journal of Virus Eradication report estimating it costs less than a dollar to produce a one-day dose of remdesivir, it's likely Gilead will make a profit. There is a lot to Gilead besides coronavirus work. The biotech company's HIV drug sales are growing, led by blockbuster Biktarvy. The drug's revenue more than doubled in the first quarter, and Gilead said that in the U.S., Biktarvy is the No. 1 prescribed HIV treatment. Looking ahead, rheumatoid arthritis drug filgotinib may be another growth driver. The FDA is currently reviewing the drug and may issue a decision at any time. Gilead has already prepared for a second-half launch and hopes for approval in Europe and Japan by the end of the year. Gilead's shares actually peaked on April 30, with a 29% gain from the start of the year. As attention turned to vaccine makers, the shares lost some steam, ultimately delivering an 18% increase for the first half. Gains moving forward might be slower than those of certain vaccine makers, but the overall path higher should be smoother.www.fool.com/investing/2020/07/19/3-t...
IN DARWIN’S FOOTSTEPS: ADAPTATION THROUGH INNOVATION IN RHEUMATOID ARTHRITIS 21 JULY 2020 | RHEUMATOLOGY
Next catalyst will be the FDA Potential approval of filgotinib and that's the most important one (biggest market). De Europese geneesmiddelenautoriteit EMA geeft een positief advies voor het gebruik van de reumapil filgontinib van Galapagos. Daarmee ligt de weg open voor de verkoop van het middel in Europa. Galapagos en zijn Amerikaanse partner Gilead moeten nog één horde nemen: de Europese Commissie. Die moet een definitief fiat geven voor de verkoop van het middel in de 27 EU-landen, Noorwegen, IJsland, Liechtenstein en het Verenigd Koninkrijk. Galapagos verwacht dat groen licht in het derde kwartaal. Het farmabedrijf laat voor het eerst weten onder welke merknaam filgotinib - in tabletten van 100 en 200 mg - in Europa op de markt zal komen: Jyseleca.Amerika Het goedkeuringsdossier voor de reumapil ligt ook bij de Amerikaanse geneesmiddelenautoriteiten op tafel. Die moet een oordeel vellen over de markttoelating van de mogelijke blockbuster op de Amerikaanse markt. Reumatische artritis is een van de tien aandoeningen waarvoor filgotinib wordt getest. Er lopen ook patiëntenproeven voor andere aandoeningen, zoals psoriatische artritis. Gilead kocht vorig jaar voor 3,5 miljard euro een inzagerecht in en exclusiviteit op alle belangrijke medicijnen die Galapagos ontwikkelt. De Amerikaanse farmareus breidde parallel zijn aandelenbelang in het Mechels bedrijf voor 1 miljard euro uit tot bijna een kwart van het kapitaal.www.tijd.be/ondernemen/farma-biotech/...
3 Biotech Stocks With Big Incoming Catalysts Cory Renauer Jul 25, 2020 at 6:56AM Biotech investors can get ready for a busy month full of stock-moving binary events. All of these companies are waiting for the FDA to make some very important approval decisions.Here's what you should know about three of the most important approval decisions expected over the next several weeks. 2. Galapagos NV: Filgotinib for rheumatoid arthritis This biotech from Belgium and its Californian partner, Gilead Sciences (NASDAQ:GILD), are eagerly awaiting an approval decision regarding filgotinib, an easy-to-swallow tablet that could become the next blockbuster treatment for rheumatoid arthritis. Neither partner has had anything to say about filgotinib's New Drug Application since they submitted it in December. Since the partners included a priority review voucher, the FDA's expected to issue an approval decision on or before Aug. 21, 2020. In the EU, the European Medicines Agency (EMA) recently recommended the European Commission (EC) grant marketing authorization to filgotinib under the brand name Jyseleca. The EC doesn't necessarily need to follow the EMA's recommendation, but it usually does. At the moment, Galapagos is a clinical-stage biotech without any products to sell. If filgotinib earns FDA approval, Galapagos will receive a tiered royalty percentage that tops out at 30% of sales as Gilead handles commercialization in the U.S. on its own. Think further ahead While FDA approvals could push these stocks up over the next several weeks, trying to chase short-term movements is a good way to underperform. While it's important to understand events that can move biotech stocks overnight, investors need to think in decades, not weeks.www.fool.com/investing/2020/07/25/3-b...
Busy schedule ahead for the Investor Relations Team. The company expects to report top-line results from the ROCELLA phase IIb trial of ‘1972 in osteoarthritis in H2. Within the fibrosis portfolio, the company expects to report top-line results from PINTA ph II trial with ‘1205 in IPF and NOVESA ph IIa data of ‘1690 in SSc.Events September 07, 2020 Kepler Cheuvreux Autumn Conference VirtualSeptember 09, 2020 Citi Biopharma Conference VirtualSeptember 10, 2020 Knowledge for Growth GhentSeptember 14, 2020 MS Global Healthcare Conference New YorkSeptember 15, 2020 Cantor Global Healthcare Conference VirtualSeptember 17, 2020 BofA Virtual London September Global Healthcare Conference VirtualSeptember 24, 2020 Bernstein 17th Annual SDC VirtualSeptember 29, 2020 J.P. Morgan CEO call 2020 VirtualOctober 01, 2020 Stifel – Immunology & Inflammation Summit VirtualNovember 17, 2020 Stifel Healthcare Conference New York
Zou het kunnen dat we deze of volgende week al een FDA approval krijgen? Als ik kijk naar Gilead/Kite's KTE-X19 dan heeft de filing op 11 december plaatsgevonden. Twee maanden later, op 10 februari, is de PRV verleend en afgelopen vrijdag 24 juli kwam de approval. Ergo; de FDA ligt voor op schema? Of vergelijk ik nu als leek de spreekwoordelijke appels met peren?
Goed punt. Zag vorige week ook onderstaande quote langskomen FDA commissioner Stephen Hahn added that in the most recent fiscal year, FDA “reached a new high for priority applications filed — 72 — and total applications filed — 166 — and again are on track to meet or exceed most of our review performance goals.” De vraag is alleen of beleggers zitten te wachten op een goedkeuring gezien de koersontwikkeling van afgelopen week. Iets van 10 jaar ben ik aandeelhouder en dan werk je toe naar de eerste goedkeuring. pffffff Als je in januari had geweten dat na de Europese blessing en vlak voor de FDA goedkeuring de koers op 165 zou staan, had je alvast hypotheek 2,3,en 4 gaan regelen. Als je toen ook nog hardop had durven zeggen dat de koers na goedkeuringen wellicht niet eens de 180 zou halen, was je waarschijnlijk aan de verkeerde kant van de vitrine in het Boerhaave museum terecht gekomen. Maar het is wat het is.
@Bosebox. ik haal mijn reactie uit analisten draadje even naar dit draadje om die ander schoon te houden.Bosebox schreef op 27 juli 2020 13:54 :
...
Opvallend dat ze Atopic Dermatitis als indicatie voor Filgo een ‘missed opportunity’ noemen. Abbvie is hier wel ingesprongen met Upadacitinib. Een grote misser dus van het vorige Gilead management, evenals het veel te traag opstarten van de Manta studies. Dat had beter gekund, maar gedane zaken nemen geen keer, en we mogen allen zeer blij zijn met de nieuwe huidige Gilead top met O’day als captain.
...
mbt Atopic Dermatitus, zou het niet onderzoeken van deze ziekte met Filgo niet uit de koker van Galapagos zelf kunnen komen ? Ten tijde van de licentie name van Filgo was er namelijk nog een veelbelovend molecuul MOR106 op dit gebied actief binnen de Gala pipeline. mbt Manta. Ook daar heeft Gala een rol gespeeld. Bezoekers aan de nieuwjaarsborrel (de eerste in Boerhaave ?) kunnen zich wellicht de uitwisseling tussen Onno en Dr Bob herinneren. De lacherige toon, over dit onderzoekje wat er wel even doorheen gefietst zou worden, staat mij nog goed bij. Management is daar tijdens de AVA in 2019 op aangesproken maar reageerde daar zeer korzelig op. Weet niet of het onder O'Day beter wordt. kijkend naar de tijdlijn van AS heb ik mijn twijfels.
Dank voor de input winx. MOR106 kan ik inkomen vanuit Gala kant, echter vanuit Gilead bekeken is niets minder dan een gemiste kans. Kan best zijn dat, zeker met Onno aan het roer, Galapagos meer invloed had destijds op voortgang en visie Filgo dan wij denken. De AS tijdlijn geef ik voordeel van de twijfel. Corona + er is duidelijk prioriteit gegeven aan PsA met opstart Penguin studies. Wellicht ivm grotere commerciële opportuniteit. Mijn kennis omtrent tijdspad, aanvraag, regelgeving, opzet, start van klinische studies schiet echter tekort om het tijdspad van AS te beoordelen.
ViewPoints: Gilead, Galapagos win small victory in fight to differentiate filgotinib (Ref: ViewPoints Desk) July 28th, 2020 By: Michael FlanaganGilead Sciences and Galapagos have argued strenuously that filgotinib is different than the rest of the JAK inhibitor crowd and their case got a boost from regulators – albeit not the ones that matter most. The backstory JAK inhibitors like Pfizer’s Xeljanz (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib) have carved out a sizable niche in the rheumatoid arthritis (RA) market thanks to their robust effectiveness and the attractive convenience of oral administration. One cloud hanging over the class is a black box that FDA has slapped on all three of the approved drugs warning about the risk of infections and thrombotic events. (See ViewPoints: AbbVie's JAK stuck in a black box.) Gilead and Galapagos are looking to horn in on the action with filgotinib, which they say is differentiated by its relative specificity for JAK1 that leads to a better safety profile. To support their claims, the partners point to data such as a pooled analysis of three Phase III trials and one Phase IIb study showing a lower thrombotic event rate for those receiving filgotinib (one event in 2,088 patients) compared to placebo (three events in 1,039 patients).What happened On July 24, Gilead and Galapagos announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for filgotinib – newly dubbed Jyseleca – for the treatment of RA in adults with moderate-to-severe RA who have not responded or tolerated one or more disease modifying anti-rheumatic drugs (DMARDs). A crucial feature of the agency’s opinion, which is expected to be finalised by the European Commission in 3Q20, is that it recommended approval of both a 100-mg and 200-mg dose of the once-daily JAK1 inhibitor.What matters most A marketing application for Jyseleca is also under review in the US, where a differentiated label is believed to be vital if Gilead and Galapagos are to make significant inroads with a fourth-to-market JAK inhibitor. The partners’ pie-in-the-sky dream is to avoid a black box warning or, barring that, for there to at least be some useful information suggestive that Jyseleca’s safety is better than the others. The EMA’s decision to give its blessing to the higher 200-mg dose of Jyseleca could thus be seen as a boost to the partners’ hopes, as higher doses of Olumiant and Rinvoq were not approved by the same agency due to concerns about thrombotic events. There is some debate among analysts about whether the EMA’s recommendation offers any hints on the FDA’s thought process. HC Wainwright analyst Debjit Chattopadhyay called this week’s news an “incremental positive” as it validated Gilead/Galapagos’ contention that all JAK inhibitors need not be treated exactly the same. “To date, Jyseleca's safety profile has been consistent with its mechanism of action, i.e., minimal impact on the EPO or JAK2 pathways, which translates into a differentiated haematologic and deep vein thrombosis/pulmonary embolism profile, the potential cornerstone in the upcoming commercial battle,” he remarked. Matthew Harrison of Morgan Stanley is more dubious about there being any read-through, noting that “while the recommendation includes both 100-mg and 200-mg doses, the 200-mg dose level had been less of a focus for EU regulators, so we do not see this outcome as surprising or indicative of what could happen in the US.”The bigger picture Rinvoq is the most recent entrant having been launched in 2H19. The drug’s market share has already shot past Olumiant and is steadily cutting away at Xeljanz’s dominant position, which key opinion leaders indicate is a credit to Rinvoq’s better efficacy profile and AbbVie’s deft marketing touch. However, for the time being anyway, those same physicians are more circumspect about whether Gilead will be able to hit the market even later and have a similarly disruptive impact. The company’s main challenges boil down to the consensus expectation that Jyseleca’s label will be similarly burdened by a black box warning, meaning that its safety profile will not be seen as sufficiently different, which may be compounded by Gilead’s lack of commercial presence in the rheumatology setting. (See Therapy Trends – Rheumatoid Arthritis: KOL Views.)What next? The Street does not have long to wait for a decision from the FDA, which is expected to reach a verdict on Jyseleca by sometime next month.www.firstwordpharma.com/node/1744430
Inflammatory Disease Pipeline (updated) FilgotinibMANTA/MANTA-RAy enrollment completion
Wall Street Trader schreef op 30 juli 2020 22:16 :
Inflammatory Disease Pipeline (updated) Filgotinib
MANTA/MANTA-RAy enrollment completion Thanks!
Wat ik toch opvallend vind op slide 21 is de expliciete vermelding van het exceptionele safety profile van Filgo in RA bij de Eular data readouts . Duidt toch nogmaals op vertrouwen en misschien toch ook een indicatie van waar zij op rekenen mbt FDA approval?
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)